Teva to create generic drug giant in $7.5bn Barr buyout
Saturday 19 July 2008
The increase in merger deals involving generic drug companies has continued apace after Israel's Teva Pharmaceuticals announced it was buying its American rival Barr, the fourth-biggest group in the sector, for $7.5bn (£3.75bn).
The friendly deal will combine the generalist group Teva with Barr, which specialises in female healthcare, giving the merged company more than 500 products and sales worth $11.9bn. Teva will pay $66.50 for each share, which represents a 32 per cent premium to Barr's average share price over the past two years and 42 per cent above where the stock closed on Wednesday. The acquisition price also includes Barr's debt.
Teva hopes the deal will cement its place as one of the leading off-patent drugs producers in the US, as well as establishing its position in Europe. The combined group has as many as 70 patent challenges in the pipeline. "The combination of our two companies provides an outstanding opportunity strategically and economically: it will enhance our market share and leadership position in the US and key global markets," said Teva's chief executive Shlomo Yanai.
Andreas Theisen, an analyst at WestLB in Germany, said the deal comes as something of a surprise. "We would not have thought that Teva was interested in the US operation where it has undoubtedly been attracted to Barr's very specialised oral contraceptive business. The price looks pretty cheap at a multiple of just 12.7 times Ebitda, most deals in the past three or four years have come at around 15 to 16 times. This certainly leaves the door open for others to bid for Barr." According to Mr Theisen, the agreement includes a $200m break clause, which is payable to Teva if Barr withdraws from the merger.
Generic drugs companies operate by producing treatments that were originally developed by the branded sector, but where patents have lapsed. Increasingly, generics groups are challenging patents in the courts. Earlier this month, Teva was dealt as blow when a New Jersey district judge awarded Astra-Zeneca a summary judgment in a case where Teva had sought to set aside the patent protecting the schizophrenia drug Seroquel. Teva conceded it had breached AstraZeneca's copyright, but claimed the branded group had acted inequitably.
Yesterday's deal is the latest in a line of merger deals involving the generic drugs industry. Last month, Japan's third-biggest pharmaceuticals group, Daiichi Sankyo, bought a 35 per cent share in India's largest generic drugs maker, Ranbaxy, for $4.6bn. One analyst in London said that the latest wave of deals was nothing new. "We have been here before and historically these deals do not work very well," said the analyst. "The only merger that has succeeded in recent times was Novartis' buyout of Sandoz."
Newcastle winger is in Argentina having chemotherapy
Returning to the stage after 20 years makes actress feel 'nauseous'
Man's attempt to avoid being impounded heavily criticised
- 1 Scottish independence: Ireland since 1919 is a lesson for Scotland in what a Yes vote means
- 2 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
- 3 Grandmas keep accidentally tagging themselves as Grandmaster Flash on Facebook
- 4 Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
- 5 Kanye West halts concert after two fans don't stand up - doesn't realise one is in wheelchair and the other disabled
Islamic State: Pope is 'being targeted by Isis', Iraqi ambassador to the Holy See warns
Jennifer Lawrence and Kate Upton nude pictures exhibition cancelled after artist concedes photos were 'stolen property'
Scottish independence referendum: A nation divided against itself
John Travolta addresses former pilot's gay romance allegations publicly for the first time: 'That was the lowest I'd ever felt'
Richard III: Two years after his body was found scientists discover how he died
Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
The political class is doing what Hitler couldn’t – destroying Britain
Scottish independence: Nationalist leader Jim Sillars threatens pro-union companies with 'day of reckoning' after independence
Scottish independence: Yes campaign feels the heat as Alex Salmond's NHS claims come under furious attack
Portuguese academic says British are 'filthy, violent and drunk'
£23m Birmingham cycle scheme is attacked by Tory councillor for not catering to the elderly
iJobs Money & Business
£20000 - £25000 per annum + OTE £35,000 first year: SThree: The SThree group i...
£20 - 24k (Uncapped Commission - £35k Year 1 OTE): Guru Careers: We are seekin...
£20 - 24k + Benefits: Guru Careers: This is a great opportunity for an enthusi...
£280 - £320 per day: Ashdown Group: The Ashdown Group have been engaged by a l...